Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Kohei Shitara Source Type: research
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Study